Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer.

adenocarcinoma biomarker cell cultures exosomes extracellular vesicles liquid biopsy non-small cell lung cancer squamous cell carcinoma tumorspheres

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Jun 2022
Historique:
received: 13 05 2022
revised: 24 06 2022
accepted: 27 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 10 7 2022
Statut: epublish

Résumé

Lung cancer is a malignant disease with high mortality and poor prognosis, frequently diagnosed at advanced stages. Nowadays, immense progress in treatment has been achieved. However, the present scenario continues to be critical, and a full comprehension of tumor progression mechanisms is required, with exosomes being potentially relevant players. Exosomes are membranous vesicles that contain biological information, which can be transported cell-to-cell and modulate relevant processes in the hallmarks of cancer. The present research aims to characterize the exosomes' cargo and study their role in NSCLC to identify biomarkers. We analyzed exosomes secreted by primary cultures and cell lines, grown in monolayer and tumorsphere formations. Exosomal DNA content showed molecular alterations, whereas RNA high-throughput analysis resulted in a pattern of differentially expressed genes depending on histology. The most significant differences were found in XAGE1B, CABYR, NKX2-1, SEPP1, CAPRIN1, and RIOK3 genes when samples from two independent cohorts of resected NSCLC patients were analyzed. We identified and validated biomarkers for adenocarcinoma and squamous cell carcinoma. Our results could represent a relevant contribution concerning exosomes in clinical practice, allowing for the identification of biomarkers that provide information regarding tumor features, prognosis and clinical behavior of the disease.

Identifiants

pubmed: 35804987
pii: cancers14133216
doi: 10.3390/cancers14133216
pmc: PMC9264915
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Signal Transduct Target Ther. 2020 Aug 3;5(1):144
pubmed: 32747657
Transl Lung Cancer Res. 2020 Oct;9(5):2214-2232
pubmed: 33209645
Signal Transduct Target Ther. 2020 Aug 5;5(1):145
pubmed: 32759948
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
Exp Cell Res. 2013 Jan 1;319(1):75-87
pubmed: 23022396
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
Nat Rev Clin Oncol. 2018 Jun;15(6):353-365
pubmed: 29599476
J Exp Clin Cancer Res. 2020 May 27;39(1):95
pubmed: 32460897
Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
Am J Cancer Res. 2018 Sep 01;8(9):1661-1673
pubmed: 30323961
Drug Discov Today. 2017 Jun;22(6):927-936
pubmed: 28288782
Onco Targets Ther. 2020 Mar 25;13:2491-2510
pubmed: 32273721
BMC Cancer. 2019 Aug 20;19(1):824
pubmed: 31429720
Nat Rev Cancer. 2005 Aug;5(8):615-25
pubmed: 16034368
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Sci Rep. 2019 Dec 27;9(1):19909
pubmed: 31882684
Mol Cancer. 2021 Jan 27;20(1):22
pubmed: 33504342
Adv Exp Med Biol. 2017;995:97-125
pubmed: 28321814
Nat Biomed Eng. 2022 Mar;6(3):232-245
pubmed: 35102279
Sci Rep. 2021 Jun 25;11(1):13323
pubmed: 34172784
Mol Cancer. 2019 Feb 8;18(1):22
pubmed: 30736860
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Mol Cancer. 2019 Apr 2;18(1):75
pubmed: 30940145
Oncoimmunology. 2016 Dec 7;6(1):e1260214
pubmed: 28197383
Int J Nanomedicine. 2020 Oct 19;15:8019-8036
pubmed: 33116515
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2022 Jan 19;12(1):972
pubmed: 35046472
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Cancer Cell. 2014 Apr 14;25(4):501-15
pubmed: 24735924
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
Clin Cancer Res. 2005 Nov 15;11(22):8055-62
pubmed: 16299236
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370304
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Transl Lung Cancer Res. 2015 Feb;4(1):67-81
pubmed: 25806347
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer Res. 2008 Feb 15;68(4):1074-82
pubmed: 18281482
Clin Transl Oncol. 2020 Jun;22(6):823-834
pubmed: 31559582
Oncotarget. 2017 Jun 22;8(34):56143-56157
pubmed: 28915579
Cancer Lett. 2013 Jan 1;328(1):160-7
pubmed: 22922091
J Thorac Dis. 2017 Oct;9(Suppl 13):S1373-S1382
pubmed: 29184676
Cancer Cell Int. 2019 Oct 01;19:251
pubmed: 31582907
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Mater Sci Eng C Mater Biol Appl. 2021 Mar;122:111914
pubmed: 33641907
PLoS One. 2018 Mar 15;13(3):e0194016
pubmed: 29543851
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
Adv Cancer Res. 2018;139:1-33
pubmed: 29941101
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
J Cell Physiol. 2020 Oct;235(10):6896-6904
pubmed: 31994191
J Thorac Oncol. 2019 Dec;14(12):2071-2083
pubmed: 31449889
Cell Mol Neurobiol. 2020 Jul;40(5):767-784
pubmed: 31853695
Cell Rep. 2017 Dec 12;21(11):3298-3309
pubmed: 29241554
J Cell Biochem. 2020 Jun;121(5-6):3286-3297
pubmed: 31960989
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Oncol Pract. 2019 Aug;15(8):e717-e727
pubmed: 31237806
Oncol Lett. 2021 Apr;21(4):249
pubmed: 33664813
Lung Cancer. 2018 Feb;116:46-54
pubmed: 29413050
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Cell Death Dis. 2019 Sep 10;10(9):660
pubmed: 31506430
Transl Cancer Res. 2021 Jun;10(6):3128-3139
pubmed: 35116621
Medicine (Baltimore). 2021 Apr 16;100(15):e25332
pubmed: 33847632
J Cell Biochem. 2020 Mar;121(3):2525-2533
pubmed: 31646690
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
Oncotarget. 2016 Aug 16;7(33):52849-52861
pubmed: 27463005
Transl Lung Cancer Res. 2020 Aug;9(4):1074-1083
pubmed: 32953486
J Am Chem Soc. 2015 Dec 23;137(50):15892-8
pubmed: 26632983
Cancer Sci. 2009 Nov;100(11):2014-21
pubmed: 19719775
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341
Mol Cancer. 2019 Mar 13;18(1):40
pubmed: 30866952
Cells. 2021 Apr 17;10(4):
pubmed: 33920536

Auteurs

Elena Duréndez-Sáez (E)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.

Silvia Calabuig-Fariñas (S)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Pathology, Universitat de València, 46010 Valencia, Spain.

Susana Torres-Martínez (S)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.

Andrea Moreno-Manuel (A)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.

Alejandro Herreros-Pomares (A)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Biotechnology, Universitat Politècnica de València, 46022 Valencia, Spain.

Eva Escorihuela (E)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.

Marais Mosqueda (M)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.

Sandra Gallach (S)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.

Ricardo Guijarro (R)

Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Surgery, Universitat de València, 46010 Valencia, Spain.
Department of Thoracic Surgery, Hospital General Universitario de Valencia, 46014 Valencia, Spain.

Eva Serna (E)

Freshage Research Group, Department of Physiology, Universitat de València, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable CIBERFES, Fundación Investigación Hospital Clínico Universitario/INCLIVA, 46010 Valencia, Spain.

Cristian Suárez-Cabrera (C)

Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Biomedical Research Institute i+12, Hospital Universitario "12 de Octubre", 28040 Madrid, Spain.
Molecular Oncology Unit, CIEMAT, 28045 Madrid, Spain.

Jesús M Paramio (JM)

Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Biomedical Research Institute i+12, Hospital Universitario "12 de Octubre", 28040 Madrid, Spain.
Molecular Oncology Unit, CIEMAT, 28045 Madrid, Spain.

Ana Blasco (A)

TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Medical Oncology, Hospital General Universitario de Valencia, 46014 Valencia, Spain.

Carlos Camps (C)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Medical Oncology, Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Department of Medicine, Universitat de València, 46010 Valencia, Spain.

Eloisa Jantus-Lewintre (E)

Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Centro de Investigación Biomédica en Red Cáncer, CIBERONC, 28029 Madrid, Spain.
Department of Biotechnology, Universitat Politècnica de València, 46022 Valencia, Spain.
Joint Unit: Nanomedicine, Centro Investigación Príncipe Felipe-Universitat Politècnica de Valencia, 46022 Valencia, Spain.

Classifications MeSH